Pharma Q3 Results Preview - Positive Attributes To Aid In Revenue Growth, Gross Margins: Axis Securities

Axis Securities Report

In Q3 FY23, the pharma sector is expected to benefit from positive attributes such as currency depreciation, fall in raw material prices, low crude prices, and correction in shipping prices which would aid in revenue growth and improvement in gross margins.

We expect the pharma universe under our coverage to report healthy aggregate revenue/Ebitda/profit after tax growth of 7.4%/9.5%/9.1% YoY. 8% depreciation in the Indian currency may majorly contribute to the overall growth of 7.4% for the last quarter.

Low single-digit growth in the U.S. market (due to intense competition) and low double-digit growth in the India business after Covid-19 business has now stabilised.

Single-digit revenue growth may be observed in Europe and the International market in Q3 FY23.

Click on the attachment to read the full report:

DISCLAIMER

This report is authored by an external party. BQ Prime does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BQ Prime.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.